Form 4: Aligos Therapeutics CFO Acquires Stock Options

Lesley Ann Calhoun, CFO of Aligos Therapeutics, acquired stock options on September 4, 2024.

Summary

• Lesley Ann Calhoun, the Chief Financial Officer of Aligos Therapeutics, Inc. (ALGS), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on September 4, 2024, where Calhoun acquired stock options.
• Calhoun acquired options to purchase 10,880 shares of Aligos Therapeutics common stock at an exercise price of $11.74 per share.
• The options vest in 48 equal monthly installments starting from September 4, 2024, and will be fully vested on the fourth anniversary of this date, contingent upon continued service.
• Following the reported transaction, Calhoun directly owns 10,880 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options can be seen as a slightly positive sign, indicating confidence, but it's not a major event.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CFO's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates